Swiss CMO's China plant up and running

nantong

China has signed off on Switzerland-based Siegfried’s new contract manufacturing plant in Nantong, and after 10 months of trial operation, the facility is open for business.

The CMO says the new facility, which is northwest of Shanghai, has a 350-cubic-meter capacity and has about 200 employees. The company said the pilot plants have been producing for 18 months and initial orders for large-scale production have been received. In addition, products will be transferred from other locations to Nantong.

The company, which also has production sites in Switzerland, Germany, France, Malta and the U.S., started construction on the China project in August 2013. At the time, it said it would have technology that was compatible with a plant in Zofingen, Switzerland, to make transfers between the two more efficient.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Last year, Siegfried also paid €270 million ($302.3 million) for BASF's ephedrine, pseudoephedrine and caffeine API businesses, as well as BASF's custom drug manufacturing operation, all in Europe.

Siegfried is not the only European drugmaker that is betting on contract manufacturing in China. German drugmaker Boehringer Ingelheim is investing in a €35 million ($44.9 million) biologics plant in Shanghai, which it expects to have operational in Q1 2017.

- here’s the release

Related Articles: 
Siegfried building plant in China 
Siegfried completes $302M deal for BASF API plants 
Boehringer Ingelheim wins first client for China biologics plan

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.